CIK 0001636282
- Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464312787
- Phone
- +1 617-651-5940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,349,597
- in 6 filings, $12.3M under 10b5-1 plans
Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 21 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-12-07 | Quinn Anthony G. Interim CEO | Purchase | +2,800 | $4.99 | $14K | 34,809 |
| 2017-12-06 | Quinn Anthony G. Interim CEO | Purchase | +4,888 | $4.92 | $24K | 32,009 |
| 2017-12-05 | York Charles N II Chief Financial Officer and VP | Purchase | +10,241 | $4.76 | $49K | 34,787 |
| 2017-12-05 | Quinn Anthony G. Director | Purchase | +5,065 | $4.93 | $25K | 27,121 |
| 2017-12-04 | York Charles N II Chief Financial Officer and VP | Purchase | +3,259 | $4.97 | $16K | 24,546 |
| 2017-12-04 | Quinn Anthony G. Director | Purchase | +7,956 | $4.98 | $40K | 22,056 |
| 2017-12-01 | York Charles N II Chief Financial Officer and VP | Purchase | +6,500 | $4.59 | $30K | 21,287 |
| 2017-12-01 | Shanafelt Armen Director | Grant or award · Director Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2017-12-01 | Quinn Anthony G. Director | Purchase | +4,100 | $4.53 | $19K | 14,100 |
| 2017-12-01 | Mahatme Sandesh Director | Grant or award · Director Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2017-12-01 | GEORGIOU GEORGE Director | Grant or award · Director Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2017-12-01 | Cox Russell J. Director | Grant or award · Director Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2017-08-31 | Quinn Anthony G. Interim CEO | Grant or award · Employee Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2017-08-22 | York Charles N II Chief Financial Officer and VP | Grant or award · Employee Stock Option (right to buy) | +58,500 | 58,500 | ||
| 2017-08-22 | Wooldridge James Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +165,000 | 165,000 | ||
| 2017-08-22 | Wooldridge James Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2017-08-22 | TYLER JOSEPH E VP, Manufacturing | Grant or award · Employee Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2017-08-22 | Schuchart Aaron Chief Business Officer | Grant or award · Employee Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2017-08-22 | Rowlinson Scott W VP, Research | Grant or award · Employee Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2017-08-15 | York Charles N II Chief Financial Officer and VP | Purchase | +1,959 | $2.52 | $5K | 14,787 |
Page 18 of 19 · 372 trades